Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain(Loyola University Chicago), William E. Barlow(SWOG Cancer Research Network), Steven Shak(Genomic Health (United States)), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), Robert B. Livingston(University of Arizona), I‐Tien Yeh(The University of Texas Health Science Center at San Antonio), Peter M. Ravdin(The University of Texas Health Science Center at San Antonio), Roberto Bugarini(Genomic Health (United States)), Frederick L. Baehner(Genomic Health (United States)), Nancy E. Davidson(UPMC Hillman Cancer Center), George W. Sledge(University Medical Center), Eric P. Winer(Dana-Farber Cancer Institute), Clifford A. Hudis(Memorial Sloan Kettering Cancer Center), James N. Ingle(Mayo Clinic in Florida), Edith A. Perez(Jacksonville College), Kathleen I. Pritchard(Sunnybrook Health Science Centre), Lois E. Shepherd(Queen's University), Julie R. Gralow(Seattle Cancer Care Alliance), Carl Yoshizawa(Genomic Health (United States)), D. Craig Allred(Washington University in St. Louis), C. Kent Osborne(Baylor College of Medicine), Daniel F. Hayes(University of Michigan–Ann Arbor)
Cited by 1,403Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis